EGFR and breast carcinoma: Tucatinib is a novel, FDA-approved agent that has demonstrated more than 1000-fold selectivity for HER2 over EGFR in in vitro assays27 and significant efficacy in clinical trials for the treatment of metastatic HER2-positive breast cancer (NCT02614794)28–32.